ÂÜŔňÂŇÂ×

Michael is a Killam Professor of Medical Genetics at the University of British Columbia, Founder and Senior Scientist at the Centre for Molecular Medicine and Therapeutics (CMMT), and a Canada Research Chair in Human Genetics and Molecular Medicine. Michael previously served as CSO and President of Global R&D at Teva and has founded a number of biotech companies including Aspreva, Neurovir, Xenon, 89bio, and Prilenia. He has authored over 900 publications and invited submissions and is the most cited author in the world for Huntington’s Disease and ABCA1. Michael holds a number of awards including the Order of Canada (2010), the Canada Gairdner Wightman Award (2011), and the Diamond Jubilee Medal (2012). He is recognized as one of the “100 Most Inspiring People” in pharma and was inducted into the Canadian Medical Hall of Fame. He was also recently named one of the 20th century’s “50 Canadians who have changed the world”. Michael has an MB, ChB MD and a PhD degree in Genetics from the University of Cape Town.